Report Description of the APAC Hodgkin Lymphoma Treatment Market Analysis

Research Scope and Assumption

• The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)


• The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis


• We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses


• All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis


• Inflation has not been accounted for in order to estimate and forecast the market


• Numbers may not add up due to rounding off

Reason to buy the report:

• Facilitate decision-making based on strong current and forecast data for APAC Hodgkin Lymphoma Treatment Market Analysis


• Develop strategies based on the latest regulatory framework


• Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market


• Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the APAC Hodgkin Lymphoma Treatment Market Analysis


• Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders


• To strategically profile key players and comprehensively analyze their market shares and core competencies


• We have technically sound team which do a deep dive research and also provide strategy based consulting analysis

APAC Hodgkin Lymphoma Treatment Market Analysis Executive Summary

Hodgkin Lymphoma is a cancer of the lymphatic system known as lymphoma. A part of the immune system. This disease is mostly common in the age group of 20 to 40 years and above the age of 55 years. In Hodgkin lymphoma, cells in the lymphatic system grow abnormally and could spread further. Advancement in the diagnosis and treatment of Hodgkin lymphoma have driven complete recovery of the patients condition. Symptoms of Hodgkin lymphoma are swelling of lymph nodes, persistent fatigue, fever, night sweats, and weight loss.

Market Size and Key Findings

The APAC Hodgkin Lymphoma Treatment Market Analysis size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

The market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period owing to an increase in prevalence of Hodgkin lymphoma cancer across the region, awareness about technological advancements, and awareness about chemotherapy for treatment of Hodgkin lymphoma.0



Market Dynamics

Market Growth Drivers Analysis

Increase in incidences of Hodgkin lymphoma and availability of standard diagnostic tools such as CT scans, X-rays. Biopsy, blood tests, bone marrow enable faster diagnosis of the Hodgkin lymphoma condition. An increase in prevalence and incidences of infection by EBV are expected to drive the market. About half of cases of Hodgkin lymphoma occur due to the infection by EBV and these are generally the classic form.

Market Restraints

Side effects from cancer treatment with radiation therapy and/ or chemotherapy for HD may increase the risk of second cancers, and other health problems such as infertility, heart diseases, lung diseases, etc. may restrain the market growth.

Competitive Landscape

Key Players

The Major players into the Hodgkin lymphoma treatment market are Alkem Laboratories, Amneal Pharmaceuticals, Inc., Baxter International Inc., Biogen Inc., Bristol-Myers Squibb Company, F Hoffmann-La Roche Ltd, Incyte Corp, Merck & Co. Inc., Seattle Genetics, Inc. and Teva Pharmaceutical Industries Ltd.

Products in Pipeline

A protein called CD30 is commonly found on the surface of Hodgkin lymphoma cells. A drug called brentuximab vedotin (Adcetris) that targets this protein has been approved as part of initial treatment for people with advanced Hodgkin lymphoma. Use of this new drug may help older patients avoid what had been the standard treatment with an especially toxic chemotherapy drug. Clinical trials are now testing brentuximab vedotin combined with other chemotherapies and immunotherapies.

Notable Recent Deals

• In June 2018 The Janssen Global Services, pharmaceutical company of Johnson and Johnson Services, Inc. announced results from a pre-planned interim analysis of the Phase 3 iNNOVATE study evaluating the investigational use of IMBRUVICA (ibrutinib) in combination with rituximab in relapsed/refractory and treatment-nave patients with Waldenstrms macroglobulinemia (WM) a form of lymphoma.


• In March 2018, the drug, Adcetris (brentuximab vedotin), was approved for use in combination with a chemotherapy regimen commonly known as AVD by FDI. Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited had collaborated to sell and market this drug.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

The Lymphoma Specialized Programs of Research Excellence (Lymphoma SPOREs) are designed to quickly move basic scientific findings into clinical settings. The Lymphoma SPOREs support the development of new immunotherapies, novel targeted therapies, and new methods for determining prognosis for individual patients.

The goal of the International Lymphoma Epidemiology Consortium (InterLymph) is to enhance collaboration among epidemiologists studying lymphoma, provide a forum for the exchange of research ideas, and create a framework for collaborating on analyses that compile data from multiple studies.

The Clinical Trial Sequencing Project (CTSP) promotes the use of genomics in NCI-sponsored clinical trials. CTSPs goal is to clarify the molecular basis of response and resistance to therapies studied. Diffuse large B-cell lymphoma is one of the cancer types under study, along with breast and renal cell carcinoma.

Within the Center for Cancer Research, the Lymphoid Malignancies Branch focuses on identifying abnormalities in the immune system and looking at molecular disorders that underlie lymphoid malignancies.